Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding, a case-control study

  • Figueiras, Adolfo
  • Estany-Gestal, Ana
  • Aguirre, Carmelo
  • Ruiz, Borja
  • Vidal Guitart, Xavier|||0000-0001-6705-4298
  • Carvajal, Alfonso
  • Salado, Inés
  • Salgado Barreira, Ángel
  • Rodella, Luca
  • Moretti, Ugo
  • Ibáñez, Luisa|||0000-0002-1175-0574
We conducted a multicenter, case-control study in which cases were patients aged more than 18 years with a diagnosis of UGIB, and controls were matched (1 : 3) by sex, age, date of admission, and hospital. Exposure was defined as the mean number of defined daily doses (DDDs) of NSAIDs metabolized by CYP2C9 in the week preceding the index date. Three DDD categories were defined (0, ≤0.5, and.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Polymorphisms Involved in Platelet Activation and Inflammatory Response on Aspirin-Related Upper Gastrointestinal Bleeding, A Case-Control Study

  • Mallah, Narmeen
  • Zapata-Cachafeiro, Maruxa
  • Aguirre, Carmelo
  • Ibarra-García, Eguzkiñe
  • Palacios-Zabalza, Itziar
  • Macías-García, Fernando
  • Domínguez-Muñoz, J. Enrique
  • Piñeiro-Lamas, María
  • Ibáñez, Luisa|||0000-0002-1175-0574
  • Vidal Guitart, Xavier|||0000-0001-6705-4298
  • Vendrell Bosch, Lourdes
  • Martin-Arias, Luis
  • Sáinz-Gil, María
  • Velasco-González, Verónica|||0000-0003-4739-9760
  • Figueiras, Adolfo
Despite the wide benefits of aspirin and its cost-effectiveness, aspirin prescriptions have been reduced due to idiosyncratic responses in susceptible individuals. Low-dose aspirin and single-nucleotide polymorphisms (SNPs) are independently associated with increased risk of gastrointestinal hemorrhage; however, to-date, no studies investigated the SNP-aspirin interaction effect on upper gastrointestinal hemorrhage (UGIH). Therefore, we aimed to evaluate the role of 25 SNPs in multiple genes involved in platelet activation, angiogenesis and inflammatory response in aspirin-related UGIH. A multicenter, full case-control study was conducted in patients exposed and unexposed to aspirin. Three hundred twenty-six cases diagnosed with UGIH were matched with 748 controls (1:3) by age, gender, health center, and recruitment date. Only adults of European origin were included. Participants were stratified by aspirin exposure and genotype [(Aspirin, wild -type), (Aspirin, wild -type), (Aspirin, genetic variation), (Aspirin, genetic variation)]. For each SNP, the Odds Ratio of UGIH and their 95% confidence intervals were estimated in each subgroup by using the generalized linear mixed models for dependent binomial variables. SNP-aspirin interaction effect was estimated through Relative Excess Risk due to Interaction (RERI) measures. We observed two categories of SNPs that might modify the risk magnitude of UGIH in aspirin consumers. Seven SNPs (rs1387180 A > G, rs2238631 T > C, rs1799964 T > C, rs5050 T > C/T > G, rs689466 T > C, rs1799983 T > A/T > G, and rs7756935 C > A) were "positive modifiers" associated with an excess of risk from aspirin exposure and carrying that genetic variation (1.75 ≤ RERI ≤ 4.95). On the contrary, the following nine SNPs (rs2243086 G > T, rs1131882 G > A, rs4311994 C > T, rs10120688 G > A, rs4251961 T > C, rs3778355 G > C, rs1330344 C > T, rs5275 A > G/A > T, and rs3779647 C > T) were "negative modifiers" and associated with a reduced risk in aspirin users (−2.74 ≤ RERI ≤ −0.95). This preliminary study suggests that polymorphisms in genes involved in platelets activity, angiogenesis and inflammatory response might modify the risk of aspirin-related UGIH. Further studies with larger sample size and in different populations are needed to confirm our findings. If confirmed, this might have great impact on public health, thanks to aspirin's prophylactic properties in diseases of high incidence and severity
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Synergism interaction between genetic polymorphisms in drug metabolizing enzymes and NSAIDs on upper gastrointestinal haemorrhage, a multicenter case-control study

  • Mallah, Narmeen
  • Zapata-Cachafeiro, Maruxa
  • Aguirre, Carmelo
  • Ibarra-García, Eguzkiñe
  • Palacios-Zabalza, Itziar
  • Macías-García, Fernando
  • Piñeiro-Lamas, María
  • Ibáñez, Luisa|||0000-0002-1175-0574
  • Vidal Guitart, Xavier|||0000-0001-6705-4298
  • Vendrell Bosch, Lourdes
  • Martin-Arias, Luis
  • Sáinz-Gil, María
  • Velasco-González, Verónica|||0000-0003-4739-9760
  • Bacariza-Cortiñas, Manuel
  • Salgado, Angel
  • Estany-Gestal, Ana
  • Figueiras, Adolfo
Interindividual genetic variations contribute to differences in patients' response to drugs as well as to the development of certain disorders. Patients who use non-steroidal anti-inflammatory drugs (NSAIDs) may develop serious gastrointestinal disorders, mainly upper gastrointestinal haemorrhage (UGIH). Studies about the interaction between NSAIDs and genetic variations on the risk of UGIH are scarce. Therefore, we investigated the effect of 16 single nucleotide polymorphisms (SNPs) involved in drug metabolism on the risk of NSAIDs-induced UGIH. We conducted a multicenter case-control study of 326 cases and 748 controls. Participants were sub-grouped into four categories according to NSAID exposure and genetic profile. We estimated odds ratios (ORs) and their 95% confidence intervals (CI) using generalized linear mixed models for dependent binomial variables and then calculated the measures of interaction, synergism index (S), and relative excess risk due to interaction (RERI). We undertook stratified analyses by the type of NSAID (aspirin, non-aspirin). We observed an excess risk of UGIH due to an interaction between any NSAID, non-aspirin NSAIDs or aspirin and carrying certain SNPs. The greatest excess risk was observed for carriers of: rs2180314:C>G [any NSAID: S = 3.30 (95%CI: 1.24-8.80), RERI = 4.39 (95%CI: 0.70-8.07); non-aspirin NSAIDs: S = 3.42 (95%CI: 1.12-10.47), RERI = 3.97 (95%CI: 0.44-7.50)], and rs4809957:A>G [any NSAID: S = 2.11 (95%CI: 0.90-4.97), RERI = 3.46 (95%CI: −0.40-7.31)]. Aspirin use by carriers of rs6664:C>T is also associated with increased risk of UGIH [OR: 2.22 (95%CI: 0.69-7.17) vs. OR: 7.72 (95%CI: 2.75-21.68)], yet larger sample size is needed to confirm this observation. The joint effect of the SNPs s2180314:C>G and rs4809957:A>G and NSAIDs are more than three times higher than the sum of their individual effects. Personalized prescriptions based on genotyping would permit a better weighing of risks and benefits from NSAID consumption
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A multicenter case-control study of the effect of e-nos VNTR polymorphism on upper gastrointestinal hemorrhage in NSAID users

  • Mallah, Narmeen
  • Zapata-Cachafeiro, Maruxa
  • Ibarra-García, Eguzkiñe
  • Palacios-Zabalza, Itziar
  • Macías García, Fernando
  • Iglesias García, Júlio
  • Piñeiro-Lamas, María
  • Ibáñez, Luisa|||0000-0002-1175-0574
  • Vidal Guitart, Xavier|||0000-0001-6705-4298
  • Vendrell Bosch, Lourdes
  • Martin-Arias, Luís
  • Sáinz Gil, María
  • Salgado Barreira, Ángel
  • Figueiras, Adolfo
Bleeding in non-steroidal anti-inflammatory drug (NSAID) users limited their prescription. This first multicenter full case-control study (325 cases and 744 controls), explored the association of e-NOS intron 4 variable number tandem repeat (VNTR) polymorphism with upper gastrointestinal hemorrhage (UGIH) in NSAID exposed and unexposed populations and assessed any interaction between this polymorphism and NSAIDs. NSAID users carrying e-NOS intron 4 wild type genotype or VNTR polymorphism have higher odds of UGIH than those unexposed to NSAIDs [Odds Ratio (OR): 6.62 (95% Confidence Interval (CI): 4.24, 10.36) and OR: 5.41 (95% CI 2.62, 11.51), respectively], with no effect modification from VNTR polymorphism-NSAIDs interaction [Relative Excess Risk due to Interaction (RERI): -1.35 (95% CI -5.73, 3.03); Synergism Index (S): 0.77 (95% CI 0.31, 1.94)]. Similar findings were obtained for aspirin exposure. Non-aspirin NSAID users who carry e-NOS intron 4 VNTR polymorphism have lower odds of UGIH [OR: 4.02 (95% CI 1.85, 8.75) than those users with wild type genotype [OR: 6.52 (95% CI 4.09, 10.38)]; though the interaction estimates are not statistically significant [RERI: -2.68 (95% CI -6.67, 1.31); S: 0.53 (95% CI 0.18, 1.55)]. This exploratory study suggests that the odds of UGIH in NSAID or aspirin users does not modify according to patient's e-NOS intron 4 genotype.